1 citations
,
December 2021 Cats likely have a reactive skin condition, while dogs may have a more complex, possibly cancerous one.
March 2026 in “Frontiers in Immunology” Regulatory T cells help heal skin wounds by reducing inflammation and promoting tissue repair.
16 citations
,
February 2005 in “British journal of dermatology/British journal of dermatology, Supplement” Lack of Vitamin D receptor changes skin structure and increases certain immune cells in the skin.
4 citations
,
September 2019 in “Biomedical Papers/Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc Czech Republic” CD2 might be a new treatment target for patchy alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Resident memory T cells and necroptosis may drive fibrosis in eosinophilic fasciitis and morphea.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
January 2011 in “Junshi yixue” A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.
November 2023 in “Journal of Dermatological Science” Cells that move well may improve hair loss treatments by entering hair follicles.
343 citations
,
March 2016 in “Nature Communications” IL-17-producing γδ T cells help improve bone healing.
13 citations
,
March 2023 in “Tissue Engineering and Regenerative Medicine” 16 citations
,
February 2013 in “Molecular Medicine Reports” CD34+ cells from fat tissue help form hair follicles and blood vessels in skin.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.
18 citations
,
February 2023 in “eLife” ILC1-like cells can independently cause alopecia areata.
March 2026 in “European journal of ecology, biology and agriculture.” Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
16 citations
,
September 2006 in “The Journal of Immunology” MILL molecules are unique immune proteins in mice that don't need TAP to appear on cell surfaces.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
16 citations
,
April 2024 in “Proceedings of the National Academy of Sciences” HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” CD25+ CD4+ Tregs and certain plasma proteins are linked to hair loss.
3 citations
,
April 2012 in “Cancer research” Mouse skin cancer progression involves a unique group of cells marked by ABCG2 and MTS24.
TLR2 is crucial for hair growth and regeneration, and boosting it can help prevent hair loss.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.